干旱区生态环境知识资源中心(Arid): CREB3L1 overexpression as a potential diagnostic marker of Philadelphia chromosome-negative myeloproliferative neoplasms

Arid

DOI	10.1111/cas.14763
	CREB3L1 overexpression as a potential diagnostic marker of Philadelphia chromosome-negative myeloproliferative neoplasms
	Morishita, Soji; Yasuda, Hajime; Yamawaki, Saya; Kawaji, Hideya; Itoh, Masayoshi; Edahiro, Yoko; Imai, Misa; Kogo, Yasushi; Tsuneda, Satoshi; Ohsaka, Akimichi; Hayashizaki, Yoshihide; Ito, Masafumi; Araki, Marito; Komatsu, Norio
通讯作者	Komatsu, N (corresponding author), 2-1-1 Hongo,Bunkyo Ku, Tokyo 1138421, Japan.
来源期刊	CANCER SCIENCE
ISSN	1347-9032
EISSN	1349-7006
出版年	2021
卷号	112 期号:2 页码:884-892
英文摘要	Discrimination of Philadelphia-negative myeloproliferative neoplasms (Ph-MPNs) from reactive hypercytosis and myelofibrosis requires a constellation of testing including driver mutation analysis and bone marrow biopsies. We searched for a biomarker that can more easily distinguish Ph-MPNs from reactive hypercytosis and myelofibrosis by using RNA-seq analysis utilizing platelet-rich plasma (PRP)-derived RNAs from patients with essential thrombocythemia (ET) and reactive thrombocytosis, and CREB3L1 was found to have an extremely high impact in discriminating the two disorders. To validate and further explore the result, expression levels of CREB3L1 in PRP were quantified by reverse-transcription quantitative PCR and compared among patients with ET, other Ph-MPNs, chronic myeloid leukemia (CML), and reactive hypercytosis and myelofibrosis. A CREB3L1 expression cutoff value determined based on PRP of 18 healthy volunteers accurately discriminated 150 driver mutation-positive Ph-MPNs from other entities (71 reactive hypercytosis and myelofibrosis, 6 CML, and 18 healthy volunteers) and showed both sensitivity and specificity of 1.0000. Importantly, CREB3L1 expression levels were significantly higher in ET compared with reactive thrombocytosis (P < .0001), and polycythemia vera compared with reactive erythrocytosis (P < .0001). Pathology-affirmed triple-negative ET (TN-ET) patients were divided into a high- and low-CREB3L1-expression group, and some patients in the low-expression group achieved a spontaneous remission during the clinical course. In conclusion, CREB3L1 analysis has the potential to single-handedly discriminate driver mutation-positive Ph-MPNs from reactive hypercytosis and myelofibrosis, and also may identify a subgroup within TN-ET showing distinct clinical features including spontaneous remission.
英文关键词	biomarker Philadelphia‐ negative myeloproliferative neoplasms platelet RNA RNA‐ seq
类型	Article
语种	英语
开放获取类型	DOAJ Gold, Green Published
收录类别	SCI-E
WOS记录号	WOS:000600510600001
WOS关键词	POLYCYTHEMIA-VERA ; JAPANESE PATIENTS ; JAK2 ; OASIS ; MUTATIONS ; FEATURES ; CANCER ; CALR
WOS类目	Oncology
WOS研究方向	Oncology
资源类型	期刊论文
条目标识符	http://119.78.100.177/qdio/handle/2XILL650/349779
作者单位	[Morishita, Soji; Ohsaka, Akimichi; Araki, Marito] Juntendo Univ, Dept Transfus Med & Stem Cell Regulat, Grad Sch Med, Tokyo, Japan; [Yasuda, Hajime; Edahiro, Yoko; Imai, Misa; Komatsu, Norio] Juntendo Univ, Dept Hematol, Grad Sch Med, Tokyo, Japan; [Yamawaki, Saya; Tsuneda, Satoshi] Waseda Univ, Dept Life Sci & Med Biosci, Tokyo, Japan; [Kawaji, Hideya; Itoh, Masayoshi; Kogo, Yasushi; Hayashizaki, Yoshihide] RIKEN Prevent Med & Diag Innovat Program, Yokohama, Kanagawa, Japan; [Ito, Masafumi] Japanese Red Cross Nagoya First Hosp, Dept Pathol, Nagoya, Aichi, Japan
推荐引用方式 GB/T 7714	Morishita, Soji,Yasuda, Hajime,Yamawaki, Saya,et al. CREB3L1 overexpression as a potential diagnostic marker of Philadelphia chromosome-negative myeloproliferative neoplasms[J],2021,112(2):884-892.
APA	Morishita, Soji.,Yasuda, Hajime.,Yamawaki, Saya.,Kawaji, Hideya.,Itoh, Masayoshi.,...&Komatsu, Norio.(2021).CREB3L1 overexpression as a potential diagnostic marker of Philadelphia chromosome-negative myeloproliferative neoplasms.CANCER SCIENCE,112(2),884-892.
MLA	Morishita, Soji,et al."CREB3L1 overexpression as a potential diagnostic marker of Philadelphia chromosome-negative myeloproliferative neoplasms".CANCER SCIENCE 112.2(2021):884-892.